Detalhe da pesquisa
1.
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
Blood
; 143(16): 1565-1575, 2024 Apr 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-38252906
2.
Mechanisms of Resistance to Noncovalent Bruton's Tyrosine Kinase Inhibitors.
N Engl J Med
; 386(8): 735-743, 2022 02 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-35196427
3.
Safety and efficacy of zandelisib plus zanubrutinib in previously treated follicular and mantle cell lymphomas.
Br J Haematol
; 204(5): 1762-1770, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38500476
4.
Genomic profiling for clinical decision making in lymphoid neoplasms.
Blood
; 140(21): 2193-2227, 2022 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36001803
5.
Validation of LymphGen classification on a 400-gene clinical next-generation sequencing panel in diffuse large B-cell lymphoma: real-world experience from a cancer center.
Haematologica
; 2024 Mar 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38497151
6.
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Haematologica
; 109(4): 1149-1162, 2024 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646671
7.
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes.
Haematologica
; 109(1): 200-208, 2024 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646672
8.
A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma.
Blood
; 137(5): 600-609, 2021 02 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33538797
9.
Clinical characteristics and outcomes of extranodal stage I diffuse large B-cell lymphoma in the rituximab era.
Blood
; 137(1): 39-48, 2021 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32730585
10.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023.
J Natl Compr Canc Netw
; 21(11): 1118-1131, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37935098
11.
Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial.
Lancet Oncol
; 23(8): 1021-1030, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35835137
12.
Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.
Blood
; 135(25): 2224-2234, 2020 06 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-32232481
13.
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.
Blood
; 136(10): 1134-1143, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32688395
14.
Prephase rituximab/prednisone therapy and aging-related, proinflammatory cytokine milieu in older, vulnerable patients with newly diagnosed diffuse large B-cell lymphoma.
Haematologica
; 107(5): 1144-1152, 2022 05 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34289656
15.
A roadmap for clinical trial design in marginal zone lymphoma.
Am J Hematol
; 97(11): 1398-1403, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36030403
16.
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
N Engl J Med
; 378(15): 1396-1407, 2018 04 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-29641966
17.
Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy.
Blood
; 133(2): 137-146, 2019 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-30341058
18.
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma.
Blood
; 133(20): 2121-2129, 2019 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30770396
19.
Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial.
Blood
; 133(18): 1964-1976, 2019 05 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30850381
20.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021.
J Natl Compr Canc Netw
; 19(11): 1218-1230, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34781267